# The Effects of Henagliflozin on Glucose Fluctuation and Immunosenescence in Type 2 Diabetes Patients on Insulin Therapy

> **NCT06818851** · PHASE4 · RECRUITING · sponsor: **Xinhua Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 64 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Henggliflozin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06818851
- **Lead sponsor:** Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-14
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-03-30
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2025-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06818851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06818851, "The Effects of Henagliflozin on Glucose Fluctuation and Immunosenescence in Type 2 Diabetes Patients on Insulin Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06818851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*